ASIRI SURGICAL HOSPITAL PLC
INTERIM FINANCIAL STATEMENT FOR THE PERIOD ENDED 30 September 2026

Asiri Surgical Hospital PLC

STATEMENT OF PROFIT OR LOSS

For the Six Months Period Ended 30 September 2026

	Group		Company	
	2026	2025	2026	2025
	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited
Revenue	4,376,336,666	3,885,875,864	3,985,329,676	3,489,028,666
Cost of Services	(2,433,834,873)	(2,193,884,903)	(2,266,685,631)	(2,038,986,032)
Gross Profit	1,942,501,793	1,691,990,960	1,718,644,045	1,450,042,634
Other Income	38,166,213	39,612,639	64,048,863	64,884,721
Administrative Expenses	(1,155,417,567)	(944,534,050)	(1,132,264,266)	(924,116,937)
Selling and Distribution Costs	(121,057,539)	(99,858,021)	(107,090,331)	(83,559,832)
Finance Cost	(165,735,849)	(142,424,689)	(206,338,203)	(166,329,366)
Finance Income	351,005,948	198,029,246	350,334,311	197,607,537
Profit Before Tax	889,462,998	742,816,086	687,334,418	538,528,758
Tax Expense	(304,300,584)	(301,122,690)	(250,090,818)	(237,746,510)
Profit for the Period	585,162,414	441,693,397	437,243,600	300,782,248
Attributable to:				
Equity holders of the parent	517,264,068	369,978,537		
Non-controlling interest	67,898,346	71,714,859		
Earnings Per Share - Basic	0.98	0.70	0.83	0.57
Dividend Per Share	0.00	0.00	0.00	0.00

Asiri Surgical Hospital PLC

STATEMENT OF COMPREHENSIVE INCOME

For the Six Months Period Ended 30 September 2026

	Group		Company	
	2026	2025	2026	2025
	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited
Profit for the Period	585,162,414	441,693,397	437,243,600	300,782,248
Other Comprehensive Income/(Loss)				
Other Comprehensive Income/(Loss) not to be reclassified to profit or loss in subsequent periods (net of tax) :				
Revaluation surplus on building	-	-	-	-
Actuarial gain/(loss) on retirement benefit liability	-	-	-	-
Net (Gain/Loss) an investment Subsidiary at FVOCI	-	-	-	-
Net (Gain/Loss) an Equity instrument Subsidiary at FVOCI	-	-	-	-
	-	-	-	-
Deferred Tax on Other Comprehensive Income	-	-	-	-
Net Other Comprehensive Income that will not to be reclassified to profit or loss in subsequent periods (net of tax)	-	-	-	-
Other Comprehensive Income for the period, net of tax	-	-	-	-
Total Comprehensive Income for the period, net of tax	585,162,414	441,693,397	437,243,600	300,782,248
Total Comprehensive Income Attributable to:				
Equity holders of the parent company	517,264,068	369,978,537		
Non-controlling interest	67,898,346	71,714,859		

Asiri Surgical Hospital PLC

STATEMENT OF PROFIT OR LOSS

For the Three Months Period Ended 30 September 2026

	Group		Company	
	2026	2025	2026	2025
	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited
Revenue	2,336,320,435	1,986,355,732	2,116,590,398	1,776,909,445
Cost of Services	(1,274,521,409)	(1,115,585,107)	(1,185,741,915)	(1,037,457,067)
Gross Profit	1,061,799,026	870,770,626	930,848,483	739,452,378
Other Income	20,369,807	19,573,399	33,366,182	32,259,486
Administrative Expenses	(595,373,051)	(483,029,211)	(583,811,394)	(473,414,893)
Selling and Distribution Costs	(63,612,414)	(47,901,415)	(55,329,903)	(37,803,596)
Finance Cost	(92,522,200)	(73,494,819)	(116,495,813)	(86,124,668)
Finance Income	185,114,717	99,372,592	185,056,580	98,965,094
Profit Before Tax	515,775,884	385,291,172	393,634,136	273,333,801
Tax Expense	(156,271,766)	(145,882,626)	(117,130,333)	(112,403,755)
Profit for the Period	359,504,119	239,408,546	276,503,803	160,930,046
Attributable to:				
Equity holders of the parent	322,823,177	200,015,171		
Non-controlling interest	36,680,942	39,393,374		
Earnings Per Share - Basic	0.61	0.38	0.52	0.30
Dividend Per Share	0.00	0.00	0.00	0.00

STATEMENT OF COMPREHENSIVE INCOME

For the Three Months Period Ended 30 September 2026

	Group		Company	
	2026 Rs. Un-audited	2025 Rs. Un-audited	2026 Rs. Un-audited	2025 Rs. Un-audited
Profit for the Period	359,504,119	239,408,547	276,503,803	160,930,046
Other Comprehensive Income/(Loss)				
Other Comprehensive Income/(Loss) not to be reclassified to profit or loss in subsequent periods (net of tax) :				
Revaluation surplus on building	-	-	-	-
Actuarial gain/(loss) on retirement benefit liability	-	-	-	-
Share of joint venture other comprehensive income (net of income tax)	-	-	-	-
	-	-	-	-
Deferred Tax on Other Comprehensive Income	-	-	-	-
Net Other Comprehensive Income not to be reclassified to profit or loss in subsequent periods (net of tax)	-	-	-	-
Other Comprehensive Income/(Loss) for the period, net of tax	-	-	-	-
Total Comprehensive Income for the period, net of tax	359,504,119	239,408,547	276,503,803	160,930,046
Attributable to:				
Equity holders of the parent	322,823,177	200,015,172		
Non-controlling interest	36,680,942	39,393,375		

STATEMENT OF FINANCIAL POSITION

Group			Group		Company	
As at 31-Mar-26 Rs. Audited	As at 31-Mar-26 Rs. Audited		As at 30-Sep-26 Rs. Un-audited	As at 30-Sep-25 Rs. Un-audited	As at 30-Sep-26 Rs. Un-audited	As at 30-Sep-25 Rs. Un-audited
		ASSETS				
		Non-current Assets				
6,101,875,793	5,718,448,922	Property, Plant and Equipment	6,529,429,330	5,642,683,803	6,164,420,544	5,288,135,202
23,454,377	23,454,377	Right-of-use Asset	42,916,282	17,067,991	42,916,282	17,067,993
-	231,908,000	Investment property	-	-	231,908,000	226,400,000
-	2,239,390,572	Investment in Subsidiary	-	-	2,239,390,573	1,881,194,730
3,258,531,934	3,258,531,934	Loans Granted to Related Parties	3,327,232,690	3,236,852,471	3,327,232,690	3,236,852,471
25,982,000	25,982,000	Non Current Assets	25,982,000	25,982,000	25,982,000	25,982,000
9,409,844,104	**11,497,715,804**		**9,925,560,302**	**8,922,586,265**	**12,031,850,089**	**10,675,632,396**
		Current Assets				
206,894,718	203,099,131	Inventories	232,158,156	159,362,426	222,292,048	152,742,390
1,724,715,053	1,787,122,558	Trade and Other Receivables	2,009,239,292	1,382,390,611	1,910,226,777	1,304,451,759
1,723,048,228	1,723,048,228	Other Current Assets	2,391,668,949	1,974,460,862	2,391,668,949	1,940,450,769
2,807,084,920	2,807,084,920	Loans Granted to Related Parties	2,924,962,069	2,681,257,840	2,924,962,069	2,681,257,839
651,378,071	150,601,651	Cash and Cash Equivalents	623,482,304	427,004,267	263,016,357	128,236,619
7,113,120,990	**6,670,956,489**		**8,181,510,770**	**6,624,476,006**	**7,712,166,200**	**6,207,139,376**
16,522,965,094	**18,168,672,293**	**Total Assets**	**18,107,071,072**	**15,547,062,271**	**19,744,016,289**	**16,882,771,772**
		EQUITY AND LIABILITIES				
1,393,327,565	1,393,327,565	Stated Capital	1,393,327,565	1,393,327,565	1,393,327,565	1,393,327,565
2,959,646,342	4,478,661,946	Other Components of Equity	2,959,646,342	2,633,391,827	4,478,661,945	3,905,525,939
3,234,476,759	2,802,106,459	Retained Earnings	3,751,740,827	2,816,843,050	3,239,350,059	2,388,533,804
7,587,450,666	**8,674,095,970**	**Share Holders' Fund**	**8,104,714,734**	**6,843,562,442**	**9,111,339,569**	**7,687,387,308**
544,916,132	-	Non-Controlling Interests	612,814,478	490,475,161	-	-
8,132,366,798	**8,674,095,970**	**Total Equity**	**8,717,529,212**	**7,334,037,603**	**9,111,339,569**	**7,687,387,308**
		Non-current Liabilities				
25,586,481	25,586,481	Lease Liability	36,679,357	25,586,491	36,679,357	25,586,491
191,385,324	191,385,324	Interest Bearing Loans and Borrowings	159,880,400	325,536,972	159,880,400	325,536,974
240,005,496	231,828,161	Employee Benefit Liability	250,532,134	193,274,432	241,567,557	186,730,560
1,396,571,685	1,980,118,936	Deferred Tax Liability	1,387,180,752	1,253,617,499	1,980,118,936	1,771,780,070
1,853,548,986	**2,428,918,902**		**1,834,272,643**	**1,798,015,394**	**2,418,246,250**	**2,309,634,095**
		Current Liabilities				
3,040,913,379	3,029,020,826	Trade and Other Payables	3,755,654,671	2,996,164,342	3,608,797,976	2,909,320,953
3,603,041	3,603,041	Dividend Payable	3,443,895	14,312,822	3,443,895	14,312,825
11,880,810	11,880,810	Lease Liability	18,508,776	5,420,400	18,508,776	5,420,400
1,646,001,314	1,646,001,314	Interest Bearing Loans and Borrowings	1,761,147,329	1,740,064,380	1,761,147,327	1,740,064,380
-	596,700,000	Loan Due to Related Party	-	-	870,683,764	613,677,257
980,400,067	924,200,731	Income Tax Payable	1,044,562,496	867,333,090	979,966,928	811,240,315
854,250,699	854,250,699	Bank Overdraft	971,952,050	791,714,240	971,881,804	791,714,240
6,537,049,309	**7,065,657,421**		**7,555,269,217**	**6,415,009,274**	**8,214,430,470**	**6,885,750,370**
16,522,965,094	**18,168,672,293**	**Total Equity and Liabilities**	**18,107,071,072**	**15,547,062,271**	**19,744,016,289**	**16,882,771,772**
14.36	16.41	Net Assets Per Share	15.34	12.95	17.24	14.55

Sgd
Mr. S.L.R Piyal
Director Finance

Sgd
Mr. Ashok Pathirage
Chairman / Managing Director

Sgd
Mr. Haresh Kaimal
Director

06th November 2026
Colombo

STATEMENT OF CHANGES IN EQUITY

For the Period Ended 30 September 2026

Group

	Attributable to equity holders of parent					Non - Controlling Interest	Total Equity
	Stated Capital Rs.	FV Reserves of Financial Assets at FVOCI Rs.	Revaluation Reserves Rs.	Retained Earnings Rs.	Total Rs.	Rs.	Rs.
Balance as at 01st April 2025	1,393,327,565	-	2,633,391,827	2,446,864,512	6,473,583,904	418,760,302	6,892,344,205
Profit for the Period	-	-	-	369,978,538	369,978,538	71,714,859	441,693,397
Other comprehensive Income	-	-	-	-	-	-	-
Total Comprehensive Income	-	-	-	369,978,538	369,978,538	71,714,859	441,693,397
Interim Dividend Paid - Ordinary Shares	-	-	-	-	-	-	-
Transfer to Retained Earnings	-	-	-	-	-	-	-
Balance as at 30th September 2025	**1,393,327,565**	-	**2,633,391,827**	**2,816,843,050**	**6,843,562,442**	**490,475,161**	**7,334,037,603**
Balance as at 01st April 2026	1,393,327,565	-	2,959,646,342	3,234,476,759	7,587,450,666	544,916,132	8,132,366,798
Profit for the Period	-	-	-	517,264,068	517,264,068	67,898,346	585,162,414
Other comprehensive Income	-	-	-	-	-	-	-
Total Comprehensive Income	-	-	-	517,264,068	517,264,068	67,898,346	585,162,414
Balance as at 30th September 2026	**1,393,327,565**	-	**2,959,646,342**	**3,751,740,827**	**8,104,714,734**	**612,814,478**	**8,717,529,212**

Company

	Stated Capital Rs.	FV Reserves of Financial Assets at FVOCI Rs.	Revaluation Reserves Rs.	Retained Earnings Rs.	Total Equity Rs.
Balance as at 01st April 2025	1,393,327,565	1,293,176,237	2,612,349,702	2,087,751,556	7,386,605,060
Profit for the Period	-	-	-	300,782,248	300,782,248
Other comprehensive Income	-	-	-	-	-
Total Comprehensive Income	-	-	-	300,782,248	300,782,248
Balance as at 30th September 2025	**1,393,327,565**	**1,293,176,237**	**2,612,349,702**	**2,388,533,804**	**7,687,387,308**
Balance as at 01st April 2026	**1,393,327,565**	**1,543,913,327**	**2,934,748,618**	**2,802,106,459**	**8,674,095,970**
Profit for the Period	-	-	-	437,243,600	437,243,600
Other comprehensive Income	-	-	-	-	-
Total Comprehensive Income	-	-	-	437,243,600	437,243,600
Balance as at 30th September 2026	**1,393,327,565**	**1,543,913,327**	**2,934,748,618**	**3,239,350,059**	**9,111,339,569**

STATEMENT OF CASH FLOWS

For the Period Ended 30 September 2026

	Group		Company	
Cash Flows From Operating Activities	**2026 Rs.**	**2025 Rs.**	**2026 Rs.**	**2025 Rs.**
Profit Before Income Tax Expense	889,462,998	742,816,086	687,334,418	538,528,758
Adjustments for				
Amortization of Right of use Asset	7,431,969	-	7,431,969	-
Depreciation	234,658,887	197,683,499	210,851,204	175,798,074
Loss on Sale of Property, Plant and Equipment	1,412,546	6,674	1,412,546	6,674
Finance Income	(351,005,948)	(198,029,246)	(350,334,311)	(197,607,537)
Finance Expense	165,735,849	142,424,689	206,338,203	166,329,366
Unrealized Foreign Currency Exchange Gain	1,551,779	1,020,624	1,551,779	1,020,624
Provision for Retirement Obligation Plan	24,574,080	22,738,498	23,666,580	21,913,498
Provision for Bad Debts	2,153,654	32,270	2,153,654	32,270
Inventory Write off	-	83,218	-	83,218
Operating Profit Before Working Capital Changes	975,975,814	908,776,313	790,406,042	706,104,945
Changes in Working Capital				
(Increase)/Decrease in Inventories	(25,263,438)	(19,466,529)	(19,192,918)	(16,815,662)
(Increase)/Decrease in Trade and Other Receivables	(286,677,893)	(859,160,326)	(125,257,872)	(780,728,795)
(Increase)/Decrease in Other Current Assets	(556,462,392)	(14,780,238)	(556,462,392)	(126,905,073)
Increase/(Decrease) in Trade and Other Payables	714,741,292	611,737,558	579,777,149	623,184,900
Increase/(Decrease) Amounts Due to Related Parties	-	-	(16,656,326)	-
	(153,662,431)	(281,669,535)	(137,792,359)	(301,264,631)
Cash Generated From Operations	822,313,383	627,106,778	652,613,683	404,840,315
Income Tax paid	(249,529,088)	(259,706,628)	(194,324,621)	(175,600,496)
Finance Costs paid	(157,444,308)	(139,031,064)	(157,406,573)	(162,935,741)
Defined Benefit Plan Costs paid	(18,385,876)	(14,334,171)	(18,265,621)	(14,192,271)
Net Cash Flows From Operating Activities	396,954,111	214,034,915	282,616,868	52,111,807
Cash Flows From/(Used in) Investing Activities				
Acquisition of Property, Plant and Equipment	(663,627,633)	(316,182,334)	(658,238,034)	(316,182,334)
Acquisition of Right of use assets	(510,641)	-	(510,641)	-
Loans Repayments from Related Parties	28,604,758	-	28,604,758	-
Finance income received	22,162,058	193,879,246	21,490,421	193,457,537
Loans Received from Related Parties	-	-	250,000,000	125,000,000
Net Cash Flows From Investing Activities	(613,371,458)	(122,303,088)	(358,653,496)	2,275,203
Cash Flows from /(Used in) Financing Activities				
Proceeds From Interest Bearing Loans and Borrowings	414,292,904	-	414,292,904	-
Repayment of Lease Liability	(12,413,418)	-	(12,413,418)	-
Repayment of Interest Bearing Loans and Borrowings	(330,900,113)	(318,002,651)	(330,900,113)	(301,025,394)
Dividend Paid	(159,144)	(88,898)	(159,144)	(88,898)
Net Cash Flows from Decrease Used in Financing Activities	70,820,229	(318,091,548)	70,820,229	(301,114,292)
Net Increase in Cash and Cash Equivalents	(145,597,119)	(226,359,721)	(5,216,399)	(246,727,282)
Cash and Cash Equivalents at the beginning of the year	(202,872,627)	(138,350,252)	(703,649,048)	(416,750,341)
Cash and Cash Equivalents at the end of the year	(348,469,746)	(364,709,973)	(708,865,447)	(663,477,623)
Cash & Cash Equivalents				
Cash and Bank Balances	623,482,304	426,456,433	263,016,357	127,688,784
Bank Overdrafts	(971,952,050)	(791,166,406)	(971,881,804)	(791,166,406)
	(348,469,746)	(364,709,973)	(708,865,447)	(663,477,623)

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the Period Ended 30 September 2026

1. Corporate Information

1.1 General

Asiri Surgical Hospital PLC ("Company") is a public limited liability Company, incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. The registered office and principal place of business is located at No. 21, Kirimandala Mawatha, Colombo 5.

1.2 Date of Authorisation for Issue

The Interim Condensed Financial Statements of the Group and the Company for the period ended 30th September 2026 were authorised for issue by the Board of Directors on 06th November 2026.

2. Basis of Preparation

The interim condensed financial statements have been prepared in accordance with Sri Lanka Accounting Standard - LKAS 34 Interim Financial Reporting. These interim condensed financial statements should be read in conjunction with the annual financial statements for the year ended 31st March 2026. These financial statements provide the information as required in terms of Rule 7.4 of the Colombo Stock Exchange. The presentation and classification of the financial statements of the previous period have been amended, where relevant, for better presentation and to be comparable with those of the current period.

3. Accounting Policies

The same accounting policies and methods of computation as stated in the annual financial statements for the year ended 31st March 2026 are followed in the preparation of these Interim Condensed Financial Statements.

4. Other Information

4.1 Loans Granted to Related Parties

This includes loans granted to Asiri Hospital Holdings PLC, The Central Hospital Limited, Asiri Hospital Matara Pvt Ltd, Softlogic Retail Pvt Ltd, Asiri Central Hospital Limited, Softlogic Communications (Pvt) Ltd, Softlogic Brands (Pvt) Ltd and interest receivable thereon. The interest is charged at prevailing market interest rates for these loans.

4.2 Other Current Assets

Other Current Assets include advances granted to related parties in the ordinary course of the Group's financial and treasury operations, amounting to Rs. 2,391,668,949 as at 30 September 2026 (30 September 2025: Rs. 1,940,450,769; 31 March 2026: Rs. 1,723,048,228).

4.3 Contingent Liabilities

A dispute has arisen with the Department of Inland Revenue with regard to the applicability of the income tax exemption for the years of assessment 2005/06 to 2014/15, in terms of the agreement entered between Asiri Surgical Hospital PLC and the Board of Investment of Sri Lanka (BOI) in 2000. With respect to the same we have received written notifications from the Tax Appeals Commission so far for the years of assessments 2005/06, 2006/07, 2007/08, 2008/09, 2009/10, 2010/11, 2011/12, 2012/13, 2013/14 and 2014/15 and the Tax payable on the same is Rs. 1.2Bn including penalty of which Rs. 591Mn was provided at 30th September 2026.

We also had filed a case in the Court of Appeal. Since there is a litigation, in accordance with Paragraph 92 of LKAS 37, we are unable to provide further information on this and associated risks, in order not to impair the outcome and/or prejudice the Company's position in this matter.

Other than above, there are no significant changes in the nature of the contingent liabilities and contingent assets which were disclosed in the Annual Report for the year ended 31 March 2026.

4.4 Capital Expenditure Commitments

There were no material commitments outstanding as at 30th September 2026 for future capital expenditure.

4.5 Comparative Information

Where necessary comparative figures have been reclassified to conform with the current year's presentation.

4.6 Share Capital

Issued and fully paid number of Ordinary Shares as at 30th September 2026 stands at 528,457,545.

5. Event after the balance sheet

No other events have occurred since the date of the Statement of Financial Position that necessitates adjustments to/or disclosures in the Provisional Accounts.

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the Period Ended 30 September 2026

6. Segment Information

The Senior Management Committee acts as the Chief Operating Decision Maker (CODM) and reviews the operating results of the Group's business units separately to support decisions on resource allocation and performance evaluation. Segment performance is assessed based on revenue and other income generated, measured on a basis consistent with the amounts reported in the Consolidated Financial Statements.

Based on the information presented to the CODM for these purposes, the Group has identified its reportable segments accordingly for the interim period.

- Pre Care which include OPD revenue, channeling revenue and OPD lab investigation services
- Post Care which include all IPD revenue including inpatient drugs and lab investigation
- Pharmaceutical which includes Pharmacy revenue

Segment	Group		Company	
	2026	2025	2026	2025
	Rs.	Rs.	Rs.	Rs.
Pre Care	1,515,107,972	1,445,779,188	1,124,100,981	1,048,931,991
Post Care	2,714,777,933	2,365,248,305	2,714,777,933	2,365,248,305
Pharmaceutical	146,450,761	74,848,371	146,450,761	74,848,371
	4,376,336,666	**3,885,875,864**	**3,985,329,676**	**3,489,028,666**

INVESTOR INFORMATION

Market Value of Shares

The market value of an ordinary share of Asiri Surgical Hospital PLC is as follows:

	Quarter ended 30-Sep-26	Quarter ended 30-Sep-25
- Highest Market Price – Rs.	17.30	15.50
- Lowest Market Price – Rs.	12.50	12.70
- Last Traded Price – Rs.	13.10	13.70

No of Shares Representing Stated Capital

	As at 30-Sep-26	As at 30-Sep-25
No of Ordinary Shares	528,457,545	528,457,545

* Earnings & net assets per share are based on 528,457,545 shares in issue as at 30th June 2026.

Statement of Shareholding of Directors

Name of Director	As at 30-Sep-26	As at 30-Sep-25
Mr. A. K. Pathirage	-	-
Mr. H. K. Kaimal	-	-
Mr. R. Selvaskadan	-	-
Mr. G.W.D.H.U. Gunawardena	-	-
Mr. Saar Shapira	-	-
Mr. I.M. Furkan	-	-
Mr. G.D.K.L. De Silva	-	-

Major Shareholdings

Twenty Largest Shareholders	30-Sep-26 No. of Shares	%	30-Sep-25 No. of Shares	%
Asiri Hospital Holdings PLC	342,094,329	64.73	422,555,413	79.96
Cargills Bank PLC/Asiri Hospital Holdings PLC	49,261,084	9.32		
Mr. D.K. Subasinghe / Mrs. S.N. Subasinghe	38,363,265	7.26	39,014,806	7.38
Mr. P.P. Subasinghe	7,297,900	1.38	8,162,598	1.54
Invenco Capital (Private) Limited Account No. 03	2,500,000	0.47		
Employees Trust Fund Board	2,347,341	0.44	4,418,750	0.84
Mr. Mohamed Hisham Jamaldeen	2,242,578	0.42		
Mr. M.R. Weerasinghe (Deceased)	2,000,000	0.38	2,000,000	0.38
Peoples Leasing & Finance PLC / S.P.S.Nishara	2,000,000	0.38		
LOLC Finance PLC/R. Magdon Ismail	1,793,673	0.34		
Mr.U. H. Palihakkara/Mrs. D.S. Palihakkara/Mr.K.D.H Palihakkara	1,352,046	0.26	1,352,046	0.26
Mrs.Chandani Vishaka Ariyaratne/ Miss.B.A. Ariyaratne	1,333,333	0.25	1,333,333	0.25
Peoples Leasing & Finance PLC / S.P.Perera	1,299,941	0.25		
Mr. Gihan Wickremasinghe	1,250,000	0.24		
Mr. M.D.N. Jayaratne	1,164,357	0.22	1,164,357	0.22
Mrs.Himali Sushama Jayaratne	1,164,356	0.22	1,164,356	0.22
Mr. W.W.D.D.S. Perera	1,100,000	0.21		
Deutsche Bank Ag-National Equity Fund	1,000,000	0.19		
Seylan Bank PLC / K.L.G.Udayananda	1,000,000	0.19		
Hatton National Bank PLC/Mr.Gerad Shamil Niranjan Peris	951,050	0.18		
	461,515,253	87.33	488,847,737	92.51
Shares held by the balance shareholdings	66,942,292	12.67	39,609,808	7.50
Total Issued Shares	528,457,545	100.00	528,457,545	100.00
Public Shareholding	137,102,132	25.94	105,902,132	20.04
Total Number of Public Shareholders	5,117		3,838	

The Float- adjusted market capitalization as at 30th September 2026 is Rs. 1,754,648,155.81

The Company is in compliance with option 5 of the CSE Listing Rules 7.13.1 (i) (a) which requires 20 % minimum public holding percentage and 500 minimum public shareholders

CORPORATE INFORMATION

Name of the Company
Asiri Surgical Hospital PLC

Registered Office
No. 21, Kirimandala Mawatha, Colombo 05, Sri Lanka. Telephone : 011 4524400
Email : info@asiri.lk
Web : www.asirihealth.com

Legal Form
A Quoted Public Company incorporated in Sri Lanka, under the Companies Act No. 17 of 1982 with limited liability.
The Company has re-registered under the Companies Act No. 07 of 2007. An undertaking approved by the Board of Investment of Sri Lanka (BOI) under the Board of Investment of Sri Lanka Law No. 4 of 1978.

Stock Exchange Listing
The Ordinary Shares of the Company are listed with the Colombo Stock Exchange.

Company Registration Number
PQ 208

Date of Incorporation
2nd March 2000

Directors
Mr. A.K. Pathirage - Chairman/Managing Director
Mr. H. K. Kaimal - Non- Independent Non- Executive
Mr. G. W.D.U.H. Gunawardena - Non - Independent Non - Executive
Mr. R. Selvaskandan - Independent Non-Executive
Mr. S. Shapira - Independent Non- Executive
Mr. M.I. Furkan - Independent Non - Executive
Mr. G.D.K.L.D. Silva - Independent Non- Executive

Auditors
Messrs Ernst & Young (Chartered Accountants) Rotunda Towers, No. 109, Galle Road, Colombo 03.

Secretaries
Messrs Softlogic Corporate Services (Pvt) Ltd. No. 14, De Fonseka Place, Colombo 05.

Stock Code
AMSL.N0000

Banks
Commercial Bank PLC
Hatton National Bank PLC
Nations Trust Bank PLC
Sampath Bank PLC
Cargills Bank Limited
National Development Bank PLC
DFCC Bank PLC
Seylan Bank PLC

Subsidiary Companies
Asiri AOI Cancer Centre (Private) Limited
No. 21, Kirimandala Mawatha, Colombo 05, Sri Lanka

Audit Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non - Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.De Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Frequency of meetings
Committee meets quarterly

Remuneration Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non - Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.De Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Frequency of meetings
Committee meets once a year

Nomination and Governance Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non - Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.D. Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Related Party Transactions Review Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non-Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.D. Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Frequency of meetings
Committee meets quarterly